Home » News » Clinical Intelligence » Once-daily Zytiga FDA-approved for prostate cancer

Once-daily Zytiga FDA-approved for prostate cancer

Tuesday, May 3, 2011

Centocor Ortho Biotech reports that Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel has been approved by the FDA.

Zytiga is an androgen biosynthesis inhibitor that works by inhibiting the CYP17 enzyme complex, which is required for the production of androgens in the testes, adrenal glands, and at the site of the tumor.

Results of the pivotal phase III, randomized, placebo-controlled, multicenter study showed that at pre-specified interim analysis, treatment with Zytiga in combination with prednisone resulted in a 35% reduction in the risk of death (14.8 months vs. 10.9 months [hazard ratio(HR) = 0.646; 95 percent CI: 0.543, 0.768; p

The most common adverse reactions were joint swelling or discomfort, hypokalemia, edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension, arrhythmia, urinary frequency, nocturia, dyspepsia and upper respiratory tract infection. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!